Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $17.1667.

A number of analysts have weighed in on the stock. Piper Sandler reissued an “overweight” rating and set a $16.00 target price (up from $8.00) on shares of Karyopharm Therapeutics in a research report on Monday, April 27th. Rodman & Renshaw raised shares of Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Cantor Fitzgerald assumed coverage on shares of Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating for the company. HC Wainwright increased their target price on shares of Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Robert W. Baird decreased their target price on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, March 25th.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its stake in shares of Karyopharm Therapeutics by 4.1% in the first quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after acquiring an additional 2,399 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter valued at $74,000. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at $45,000. Hsbc Holdings PLC acquired a new stake in shares of Karyopharm Therapeutics in the first quarter valued at $66,000. Finally, State Street Corp raised its stake in shares of Karyopharm Therapeutics by 27.2% in the fourth quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after acquiring an additional 12,600 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI opened at $8.16 on Friday. Karyopharm Therapeutics has a one year low of $3.65 and a one year high of $10.99. The company has a 50 day moving average of $7.79 and a 200-day moving average of $7.32. The stock has a market cap of $184.91 million, a price-to-earnings ratio of -0.54 and a beta of 0.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.21. The firm had revenue of $35.07 million for the quarter, compared to the consensus estimate of $31.40 million. Equities research analysts anticipate that Karyopharm Therapeutics will post -3.52 earnings per share for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.